Elsevier

The Lancet Neurology

Volume 5, Issue 7, July 2006, Pages 589-602
The Lancet Neurology

Review
Seminar on choreas

https://doi.org/10.1016/S1474-4422(06)70494-XGet rights and content

Summary

Chorea is one of the major types of involuntary movement disorders originating from dysfunctional neuronal networks interconnecting the basal ganglia and frontal cortical motor areas. The syndrome is characterised by a continuous flow of random, brief, involuntary muscle contractions and can result from a wide variety of causes. Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichorea in patients with lacunar stroke, but it can be a challenging and complex task in rare autoimmune or genetic choreas. Principles of management focus on establishing an aetiological classification and, if possible, removal of the cause. Preventive strategies may be possible in Huntington's disease where genetic counselling plays a major part. In this review we summarise the current understanding of the neuroanatomy and pathophysiology of chorea, its major aetiological classes, and principles of diagnostic work-up and management.

Introduction

The term “chorea” entered medical writings through descriptions of religiously inspired outbreaks of mass hysteria in the middle ages—coincident with outbreaks of the plague in central Europe—when pilgrims engaged in ecstatic jumping or dancing movements for hours on end to the point of delirium and exhaustion.1 These rituals were associated with various saints the worshippers called on, of whom Saint Vitus became the most widely known, and “Saint Vitus Dance” persisted as a synonymous term for chorea in 20th century textbooks of neurology. Paracelsus was probably the first to make a distinction between “chorea naturalis” (a true organic medical disorder) and non-organic forms, which he classified into “chorea imaginativa” and “chorea lasciva”.2 Thomas Sydenham further developed the concept of organic causes of chorea in the late 17th century with his description of childhood chorea.3 The association between Sydenham's chorea, rheumatic fever, and endocarditis, however, was not appreciated before the 19th century, by which time there was also clear recognition of hereditary chorea through the concise report by George Huntington on affected families in the state of New York.4 Today, chorea is recognised as one of the major categories of movement disorders caused by dysfunctional neuronal networks connecting the basal ganglia and motor cortical areas. Choreas can be associated with a plethora of different causes.

Section snippets

Definition and clinical phenotype

Chorea is defined as a syndrome characterised by abrupt involuntary movements resulting from a continuous flow of random muscle contractions. The pattern of movement can sometimes seem playful and convey a feeling of restlessness to the observer. When choreic movements are more severe, assuming a flinging, sometimes violent, character, they are called ballism. Regardless of its cause, chorea has the same features. The differential diagnosis of choreic syndromes relies not so much on differences

Neuroanatomy and neurophysiology of chorea

Chorea results from dysfunction within a complex neuronal network interconnecting motor cortical areas and a group of subcortical nuclei collectively termed the basal ganglia. The latter include the caudate nucleus, putamen, external and internal segments of the globus pallidus (GPe and GPi) as well as associated structures such as the subthalamic nucleus and the substantia nigra (figure 1).

Over the past 15 years, there has been substantial progress in understanding how these corticosubcortical

Aetiological classification of choreas

The neurophysiological imbalance causing chorea can result from many diverse causes including infections, autoimmune disease, genetic mutations, neurodegeneration, stroke, neoplasms, drug-exposure, and metabolic diseases (panel 1).

Diagnostic work-up

Clinical differential diagnosis is guided by age at onset, family and drug histories, associated non-choreic symptoms, course of illness, and ancillary tests (figure 4).

Principles of management

Therapeutic management of chorea should aim to remove the cause and this can be successful in drug-induced chorea, metabolic or endocrine choreas, and to some extent even in autoimmune choreas like Sydenham's chorea with penicillin prophylaxis. Preventive strategies come into play in genetic choreas like Huntington's disease, where careful genetic counselling of affected patients and their relatives is needed. In most choreic syndromes seen in clinical practice, causal therapies are not

Conclusion

Although easily diagnosed as a syndrome based on a characteristic and distinctive pattern of involuntary movements, the differential diagnosis of chorea is complex, including genetic neurodegenerative diseases like Huntington's disease, autoimmune processes targeting the basal ganglia like Sydenham's chorea, structural basal ganglia lesions, or various drug-induced, toxic, or metabolic insults to basal ganglia–cortical networks. A carefully taken history will give clues to common causes like

Search strategies and selection criteria

References for this Review were identified by searches of MEDLINE until April 2006 with the terms “chorea”, “Huntington's disease”, “Sydenham's chorea”, “PANDAS”, “hemiballism”, and “drug-induced chorea”. References were also selected from relevant articles and chapters of recent books on movement disorders. Only papers published in English were included

References (159)

  • CG Goetz et al.

    History of movement disorders as a neurological specialty: Part 14 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000

    Mov Disord

    (2001)
  • Paracelsus. Von den krankheiten so die Vernunfft berauben....
  • T Sydenham

    Schedula monitoria de novae febris ingressu

    (1686)
  • G Huntington

    On chorea

    The Medical and Surgical Reporter: A Weekly Journal

    (1872)
  • JW Mink

    The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns

    Arch Neurol

    (2003)
  • JA Obeso et al.

    The basal ganglia and disorders of movement: pathophysiological mechanisms

    News Physiol Sci

    (2002)
  • E Moro et al.

    Bilateral globus pallidus stimulation for Huntington's disease

    Ann Neurol

    (2004)
  • RJ Ferrante et al.

    Selective sparing of a class of striatal neurons in Huntington's disease

    Science

    (1985)
  • RL Margolis et al.

    Diagnosis of Huntington disease

    Clin Chem

    (2003)
  • SE Folstein et al.

    Huntington disease in Maryland: clinical aspects of racial variation

    Am J Hum Genet

    (1987)
  • G Evers-Kiebooms et al.

    Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study

    Eur J Hum Genet

    (2002)
  • MA Ramos-Arroyo et al.

    Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing

    J Neurol Neurosurg Psychiatry

    (2005)
  • EW Almqvist et al.

    High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia

    Clin Genet

    (2001)
  • MR Hayden et al.

    Huntington's chorea on the island of Mauritius

    S Afr Med J

    (1981)
  • E Kokmen et al.

    Incidence and prevalence of Huntington's disease in Olmsted County, Minnesota (1950 through 1989)

    Arch Neurol

    (1994)
  • A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

    Cell

    (1993)
  • KM Biglan et al.

    Huntington's Disease

  • DC Rubinsztein et al.

    Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats

    Am J Hum Genet

    (1996)
  • NG Ranen et al.

    Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease

    Am J Hum Genet

    (1995)
  • F Laccone et al.

    DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland

    Neurology

    (1999)
  • M Duyao et al.

    Trinucleotide repeat length instability and age of onset in Huntington's disease

    Nat Genet

    (1993)
  • SE Andrew et al.

    The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

    Nat Genet

    (1993)
  • RJ Leigh et al.

    Abnormal ocular motor control in Huntington's disease

    Neurology

    (1983)
  • F Carella et al.

    Adult onset myoclonic Huntington's disease

    Mov Disord

    (1993)
  • J Jankovic et al.

    Tourettism associated with Huntington's disease

    Mov Disord

    (1995)
  • I Reuter et al.

    Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome

    J Neurol Neurosurg Psychiatry

    (2000)
  • EK Tan et al.

    Bruxism in Huntington's disease

    Mov Disord

    (2000)
  • ED Caine et al.

    Psychiatric syndromes in Huntington's disease

    Am J Psychiatry

    (1983)
  • MF Mendez

    Huntington's disease: update and review of neuropsychiatric aspects

    Int J Psychiatry Med

    (1994)
  • M Schoenfeld et al.

    Increased rate of suicide among patients with Huntington's disease

    J Neurol Neurosurg Psychiatry

    (1984)
  • R Shiwach

    Psychopathology in Huntington's disease patients

    Acta Psychiatr Scand

    (1994)
  • A Rosenblatt et al.

    Clinical management of aggression and frontal syndromes in Huntington's disease

  • M Guttman et al.

    Clinical management of psychosis and mood disorders in Huntington's disease

  • AK Ho et al.

    Profile of cognitive progression in early Huntington's disease

    Neurology

    (2003)
  • AD Lawrence et al.

    Executive and mnemonic functions in early Huntington's disease

    Brain

    (1996)
  • SC Kirkwood et al.

    Progression of symptoms in the early and middle stages of Huntington disease

    Arch Neurol

    (2001)
  • F Marshall

    Clinical features and treatment of Huntington's disease

  • SA Sorensen et al.

    Causes of death in patients with Huntington's disease and in unaffected first degree relatives

    J Med Genet

    (1992)
  • DJ Lanska et al.

    Conditions associated with Huntington's disease at death. A case-control study

    Arch Neurol

    (1988)
  • RM Bonelli et al.

    Huntington's disease: present treatments and future therapeutic modalities

    Int Clin Psychopharmacol

    (2004)
  • Cited by (240)

    • Technologies for the management of hyperkinetic movement disorders

      2024, Handbook of Digital Technologies in Movement Disorders
    • Tremor and abnormal involuntary movement of the hand

      2023, Revue du Rhumatisme (Edition Francaise)
    View all citing articles on Scopus
    View full text